Schalken JA - Search Results

1

Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project.

van Gils MP, Stenman UH, Schalken JA, Schröder FH, Luider TM, Lilja H, Bjartell A, Hamdy FC, Pettersson KS, Bischoff R, Takalo H, Nilsson O, Mulders PF, Bangma CH. van Gils MP, et al. Among authors: schalken ja. Eur Urol. 2005 Dec;48(6):1031-41. doi: 10.1016/j.eururo.2005.06.009. Epub 2005 Jul 1. Eur Urol. 2005. PMID: 16054748 Review.

2

Identification of new prostate cancer progression markers by differential hybridization analysis.

Schalken JA, Debruyne FM. Schalken JA, et al. Eur Urol. 1992;21 Suppl 1:60-5. doi: 10.1159/000474893. Eur Urol. 1992. PMID: 1425840 Review.

3

Quantitative light microscopy in urological oncology.

van der Poel HG, Schaafsma HE, Vooijs GP, Debruyne FM, Schalken JA. van der Poel HG, et al. Among authors: schalken ja. J Urol. 1992 Jul;148(1):1-13. doi: 10.1016/s0022-5347(17)36494-7. J Urol. 1992. PMID: 1613843 Review. No abstract available.

4

Androgen receptors in endocrine-therapy-resistant human prostate cancer.

van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W, Trapman J. van der Kwast TH, et al. Among authors: schalken j. Int J Cancer. 1991 May 10;48(2):189-93. doi: 10.1002/ijc.2910480206. Int J Cancer. 1991. PMID: 1708363

5

Molecular methods for predicting the metastatic potential of prostate cancer.

Schalken JA. Schalken JA. Cancer Surv. 1991;11:43-54. Cancer Surv. 1991. PMID: 1726788 Review.

6

The Heinrich Warner Prize 1989: the use of differential hybridization analysis to identify markers for diagnosis of urogenital cancer.

Schalken JA. Schalken JA. Eur Urol. 1990;18 Suppl 2:52-7. doi: 10.1159/000463965. Eur Urol. 1990. PMID: 2226612 Review. No abstract available.

7

Expression of markers for transitional cell carcinoma in normal bladder mucosa of patients with bladder cancer.

Witjes JA, Umbas R, Debruyne FM, Schalken JA. Witjes JA, et al. Among authors: schalken ja. J Urol. 1995 Dec;154(6):2185-9. J Urol. 1995. PMID: 7500486

8

Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy.

Cornel EB, Smits GA, Oosterhof GO, Karthaus HF, Deburyne FM, Schalken JA, Heerschap A. Cornel EB, et al. Among authors: schalken ja. J Urol. 1993 Dec;150(6):2019-24. doi: 10.1016/s0022-5347(17)35957-8. J Urol. 1993. PMID: 7693985

9

Tumor heterogeneity as prognostic factor in patients with low-stage (T1-3N0M0) renal-cell carcinoma.

van der Poel HG, Mulders PF, Oosterhof GO, Schaafsma HE, Hendriks JC, Schalken JA, Debruyne FM. van der Poel HG, et al. Among authors: schalken ja. Investig Urol (Berl). 1994;5:60-5. Investig Urol (Berl). 1994. PMID: 7719322 No abstract available.

10

Karyometric analysis of intra-tumour heterogeneity in prostate adenocarcinoma.

van der Poel HG, Mulders PF, Aalders TW, Oosterhof GO, Debruyne FM, Schalken JA. van der Poel HG, et al. Among authors: schalken ja. Anal Cell Pathol. 1994 Aug;7(2):153-70. Anal Cell Pathol. 1994. PMID: 7993825

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

420 results

Search Page